Table 3.
Baseline Results.
| Strategy | Abem + NSAI |
Palbo + NSAI |
Ribo + NSAI |
Placebo + NSAI |
|---|---|---|---|---|
| Cost, $ | ||||
| Progression-free survival | 40,164 | 48,202 | 109,132 | 8683 |
| Overall | 83,345 | 91,134 | 152,001 | 70,743 |
| QALYs | ||||
| Progression-free survival | 2.22 | 2.16 | 2.15 | 1.92 |
| Overall | 4.16 | 4.09 | 4.08 | 3.78 |
| LYs | 6.51 | 6.43 | 6.40 | 6.00 |
| ICUR, $/QALY a | 33,163 | 65,777 | 270,860 | — |
| ICER, $/LY a | 24,710 | 47,421 | 203,145 | — |
| INHB, QALY a | 0.05 | −0.23 | −1.84 | — |
| INMB, $ a | 1849 | −8602 | −69,849 | — |
a Compared with placebo + NSAI group. NSAI, letrozole or anastrozole; Abem + NSAI, abemaciclib plus NSAI; Palbo + NSAI, palbociclib plus NSAI; Ribo + NSAI, ribociclib plus NSAI; placebo + NSAI, placebo plus NSAI; ICUR, incremental cost-utility ratio; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; INMB, incremental net monetary benefit; QALY, quality-adjusted life-year; LY, life year.